NewGenIvf Group Limited Class A Ordinary Shares logo

NewGenIvf Group Limited Class A Ordinary Shares(NIVF)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.23
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NIVF

11/13/2026: NIVF (1-star) is currently NOT-A-BUY. Pass it for now.

NewGenIvf Group is a diversified healthcare and technology investment entity that transitioned from a regional fertility clinic operator in Southeast Asia to an emerging player in medical technology. The company's strengths include a multi-jurisdictional clinical presence and recent pivots into higher-margin cytometry intellectual property. Its growth story hinges on international expansion, particularly in the UAE, and the successful scaling of its technology ventures. However, investors face substantial risks from low liquidity, extreme price volatility, and the complexities of navigating regulatory environments in both healthcare and digital assets. This stock may suit speculative investors who are comfortable with the high-risk, high-reward nature of micro-cap healthcare innovators.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile the company targets high-growth segments, its micro-cap status and volatility create significant execution risk.
Momentum investorStrong fit while signal remains positiveThe stock frequently exhibits extreme price swings due to low float, attracting short-term momentum traders.
Value investorWeak fitValuation is difficult to ascertain given the pivot toward early-stage technology and volatile earnings history.
Dividend investorWeak fitThe company does not pay dividends and is currently in an capital-intensive growth and restructuring phase.
Low-risk investorWeak fitHigh volatility and the risks inherent in micro-cap biotech/tech investing make this unsuitable for conservative portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow liquidity and small market cap lead to frequent, sharp price movements.
Valuation riskHighThe company's pivot to technology makes traditional valuation multiples less reliable.
Competition risk (Healthcare platforms)Medium / highNewGenIvf competes against well-funded healthcare platforms in regional markets.
Business qualityMediumThe company is transitioning from a traditional clinic operator to a more complex investment platform.
Dividend incomeLow / noneNo income potential exists for investors seeking dividends.
Execution riskHighExecuting on cross-border tech expansion while maintaining clinic performance is highly complex.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 0.37M USD
Price to earnings Ratio -
1Y Target Price 4066.56
Price to earnings Ratio -
1Y Target Price 4066.56
Volume (30-day avg) 2.2M shares
Beta 0.17
52 Weeks Range 0.19 - 7257.60
Updated Date 11/14/2026
52 Weeks Range 0.19 - 7257.60
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -27786.36

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Care Facilities

BUY participation
88.9%
Active BUY / eligible
8 / 9
30-Day BUY Count Change
+6

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
NIVF receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft quantitative characteristics, and soft analyst coverage.

Company Fundamentals

★★★★★
NIVF has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and soft ownership. In FY2025 versus FY2024, strong earnings growth (+1981.8%) and strong profitability (net margin 209.0%) are partially offset by weak cash generation (FCF margin -352.8%), negative revenue growth (-13.0%), modest insider ownership of 3.16%.

Financial Health Rating

★★★★★
NIVF's financial health is supported by solid profitability, including gross margin of 20.2% and operating margin of -226.9%. Operating efficiency is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is NIVF's strongest growth driver at +1981.8% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (-13.0%, negative) and free-cash-flow growth (-100.5%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 0.3% (soft) and 2.2% of outstanding shares are publicly tradable (soft). Insider ownership of 3.16% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

UBS Group AG 0.22%
Tower Research Capital LLC 0.04%
SBI Securities Co Ltd 0.00%
Morgan Stanley - Brokerage Accounts 0.00%

Unit Economics (Per $1K Revenue)

★★★★★
NIVF generates approximately $202 of gross profit, $-2,269 of operating income, and $-3,528 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
NIVF has a relatively low-volatility profile. No single quantitative factor dominates as a drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
IVF ServicesClinical procedures such as IVF, ICSI, and egg freezing in Southeast Asia.This is the core business providing stable but geographically concentrated revenue.
Healthcare TechnologyLicensing or leasing advanced cytometry and cell-sorting platforms.This is a new, speculative growth area aimed at higher-margin tech revenue.
GeographyOperations in Thailand, Cambodia, Hong Kong, and Kyrgyzstan.The company's fortunes are tied to the economic and regulatory environments of these specific Asian regions.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 997.28K
Price to Sales(TTM) 0.08
Enterprise Value 997.28K
Price to Sales(TTM) 0.08
Enterprise Value to Revenue 0.22
Enterprise Value to EBITDA 0.34
Shares Outstanding 1.59M
Shares Floating 35.61K
Shares Outstanding 1.59M
Shares Floating 35.61K
Percent Insiders 3.16
Percent Institutions 0.31

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.